Skip to content
drillr.ai
Sign up

02575.HK

Xuanzhubio-b

HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN

HKD 9.26
+1.82%
Ask drillr

  • Sep 17, 2026, 13:31 UTC

    Xuanzhu Biopharm (02575) announced it is in preliminary discussions with an unidentified party regarding a potential acquisition, with no formal agreement signed as of the announcement date.

    Source:

  • Sep 17, 2026, 08:12 UTC

    Hong Kong's Hang Seng Index closed down 109 points, or 0.4%, at 24,604 on September 17, 2026, with the Hang Seng Tech Index falling 14 points to 4,310.

    Source:

  • Sep 17, 2026, 05:15 UTC

    Shares of Xuanzhu Biopharm-B (02575) triggered the Hong Kong market volatility control mechanism at 13:15:01, entering a cooling-off period that will end at 13:20:01, with a price ceiling of HK$10.31 and floor of HK$6.88.

    Source:

  • Sep 3, 2026, 09:16 UTC

    Xuanzhu Biopharmaceutical signed a tripartite commercial agreement with Innobic (Asia) and ZaoAn International to grant exclusive commercialization rights for Piroxiclib tablets in Thailand, effective until June 30, 2036.

    Source:

  • Aug 26, 2026, 04:10 UTC

    Xuanzhu Biopharmaceutical reported interim results for the six months ended June 2026, with revenue of RMB 69.441 million, up 288.1% year-on-year, and a narrowed net loss of RMB 75.34 million.

    Source:

  • Jul 20, 2026, 01:38 UTC

    Xuanzhu Biotech (02575.HK) was ordered by an arbitration tribunal to pay approximately 9.33 million yuan due to a technology transfer contract dispute.

    Source:

  • Jul 19, 2026, 11:10 UTC

    Xuanzhu Biopharmaceutical (02575) was ordered by CIETAC to pay 9.33 million yuan in a technology transfer contract dispute.

    Source: